PL2564846T3 - Sposób leczenia nowotworów hematologicznych z zastosowaniem inhibitorów PNP takich jak forodezyna w skojarzeniu ze środkami anty-CD20 - Google Patents

Sposób leczenia nowotworów hematologicznych z zastosowaniem inhibitorów PNP takich jak forodezyna w skojarzeniu ze środkami anty-CD20

Info

Publication number
PL2564846T3
PL2564846T3 PL12177257T PL12177257T PL2564846T3 PL 2564846 T3 PL2564846 T3 PL 2564846T3 PL 12177257 T PL12177257 T PL 12177257T PL 12177257 T PL12177257 T PL 12177257T PL 2564846 T3 PL2564846 T3 PL 2564846T3
Authority
PL
Poland
Prior art keywords
forodesine
agents
methods
combination
hematologic cancers
Prior art date
Application number
PL12177257T
Other languages
English (en)
Inventor
Shanta Bantia
Philip Breitfeld
Yarlagadda Sudhakara Babu
Original Assignee
Biocryst Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharmaceuticals, Inc. filed Critical Biocryst Pharmaceuticals, Inc.
Publication of PL2564846T3 publication Critical patent/PL2564846T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL12177257T 2007-12-10 2008-12-10 Sposób leczenia nowotworów hematologicznych z zastosowaniem inhibitorów PNP takich jak forodezyna w skojarzeniu ze środkami anty-CD20 PL2564846T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1276207P 2007-12-10 2007-12-10
EP12177257.8A EP2564846B1 (en) 2007-12-10 2008-12-10 Methods of treating hematologic cancers using PNP inhibitors such as forodesine in combination with Anti-CD20 agents
EP08860419A EP2237778A2 (en) 2007-12-10 2008-12-10 Methods of treating hematologic cancers using pnp inhibitors such as forodesine in combination with alkylating agents or anti-cd20 agents

Publications (1)

Publication Number Publication Date
PL2564846T3 true PL2564846T3 (pl) 2018-08-31

Family

ID=40431122

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12177257T PL2564846T3 (pl) 2007-12-10 2008-12-10 Sposób leczenia nowotworów hematologicznych z zastosowaniem inhibitorów PNP takich jak forodezyna w skojarzeniu ze środkami anty-CD20

Country Status (26)

Country Link
US (5) US20110038858A1 (pl)
EP (3) EP2581083A1 (pl)
JP (2) JP5543362B2 (pl)
KR (1) KR101545367B1 (pl)
CN (2) CN103736091B (pl)
AU (1) AU2008335167B2 (pl)
CA (2) CA2881035C (pl)
CY (1) CY1120203T1 (pl)
DK (1) DK2564846T3 (pl)
EA (2) EA018415B1 (pl)
ES (1) ES2670714T3 (pl)
GE (2) GEP20135855B (pl)
HR (1) HRP20180712T1 (pl)
HU (1) HUE037342T2 (pl)
IL (1) IL206264A (pl)
LT (1) LT2564846T (pl)
MY (2) MY193789A (pl)
NO (1) NO2564846T3 (pl)
NZ (3) NZ617989A (pl)
PH (1) PH12014501454B1 (pl)
PL (1) PL2564846T3 (pl)
PT (1) PT2564846T (pl)
SG (1) SG188870A1 (pl)
SI (1) SI2564846T1 (pl)
UA (2) UA104579C2 (pl)
WO (1) WO2009076455A2 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014205199A2 (en) 2013-06-22 2014-12-24 Nitor Therapeutics Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
WO2016022166A1 (en) * 2014-08-07 2016-02-11 Nitor Therapeutics Use of pnp inhibitor to treat relapse of malignancy after hematopoietic stem cell transplant

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US199697A (en) 1878-01-29 Improvement in butter-sharers
ES2106732T3 (es) 1989-02-27 1997-11-16 Biocryst Pharm Inc Desazaguaninas substituidas en 9 y no substituidas en 8.
US4985433A (en) 1989-10-31 1991-01-15 Biocryst, Inc. 2-amino-7-(pyridinylmethyl)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
US5008270A (en) 1989-10-31 1991-04-16 Biocryst, Inc. 2-amino-7-(heterocyclomethyl)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
US5008265A (en) 1989-10-31 1991-04-16 Biocryst, Inc. 2-amino-7-(alicyclomethyl)-3H,5H,-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
US4985434A (en) 1989-10-31 1991-01-15 Biocryst, Inc. 7-substituted derivatives of 2-amino-3H,5H-pyrrolo(3,2-d)pyrimidin-4-ones and pharamceutical uses and compositions containing the same
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
HUT77436A (hu) * 1994-10-05 1998-04-28 Darwin Discovery Limited Purin- és guaninszármazékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk gyógyszerkészítmények előállítására
KR101092132B1 (ko) 1998-11-09 2011-12-12 바이오겐 아이덱 인크. 키메라 항-ｃｄ２０항체를 이용한 순환성 종양세포와 관련된 혈액학적 악성종양의 치료법
US6387923B2 (en) * 2000-03-22 2002-05-14 Biocryst Pharmacueticals, Inc. Imminoribitol PNP inhibitors, preparation thereof and use thereof
DE10306724A1 (de) * 2002-02-28 2003-09-18 G O T Therapeutics Gmbh Vesikuläre Verkapselung von Bendamustin
CA2672000C (en) * 2002-05-17 2011-11-29 Celgene Corporation Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of lymphoma
ES2389532T3 (es) * 2005-06-29 2012-10-29 Threshold Pharmaceuticals, Inc. Profármacos alquilantes de fosforamidato
CA2647282A1 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy

Also Published As

Publication number Publication date
WO2009076455A3 (en) 2009-08-27
EA201070669A1 (ru) 2010-12-30
CN101969947B (zh) 2014-10-22
KR20100101139A (ko) 2010-09-16
MY163023A (en) 2017-07-31
EP2581083A1 (en) 2013-04-17
EA018415B1 (ru) 2013-07-30
MY193789A (en) 2022-10-27
NZ617989A (en) 2015-05-29
PH12014501454A1 (en) 2016-01-18
IL206264A (en) 2017-04-30
CA2881035A1 (en) 2009-06-18
CA2708606A1 (en) 2009-06-18
CN103736091A (zh) 2014-04-23
US11110092B2 (en) 2021-09-07
CN101969947A (zh) 2011-02-09
HUE037342T2 (hu) 2018-08-28
IL206264A0 (en) 2010-12-30
DK2564846T3 (en) 2018-05-22
CY1120203T1 (el) 2018-12-12
EP2237778A2 (en) 2010-10-13
US20240100055A1 (en) 2024-03-28
EA201370055A1 (ru) 2013-11-29
NZ601072A (en) 2014-01-31
PH12014501454B1 (en) 2016-01-18
JP2014094962A (ja) 2014-05-22
EP2564846B1 (en) 2018-02-28
US20220040188A1 (en) 2022-02-10
ES2670714T3 (es) 2018-05-31
JP5543362B2 (ja) 2014-07-09
EP2564846A1 (en) 2013-03-06
EA025340B1 (ru) 2016-12-30
NZ586416A (en) 2012-07-27
CA2881035C (en) 2019-04-16
JP2011506345A (ja) 2011-03-03
US20110038858A1 (en) 2011-02-17
KR101545367B1 (ko) 2015-08-18
GEP20156288B (en) 2015-05-25
CA2708606C (en) 2015-04-28
SG188870A1 (en) 2013-04-30
CN103736091B (zh) 2016-09-28
GEP20135855B (en) 2013-06-25
AU2008335167B2 (en) 2014-02-13
US20140178372A1 (en) 2014-06-26
UA109571C2 (uk) 2015-09-10
LT2564846T (lt) 2018-05-10
WO2009076455A2 (en) 2009-06-18
UA104579C2 (uk) 2014-02-25
HRP20180712T1 (hr) 2018-06-15
PT2564846T (pt) 2018-05-23
NO2564846T3 (pl) 2018-07-28
AU2008335167A1 (en) 2009-06-18
US20190255058A1 (en) 2019-08-22
SI2564846T1 (en) 2018-06-29

Similar Documents

Publication Publication Date Title
IL257681A (en) Methods and compositions for the treatment of cancer
IL205682A0 (en) Amino triazoles as pi3k inhibitors
SI2429574T1 (sl) Sestavki in metode za zdravljenje hematoloških rakov, ki ciljajo interakcijo SIRP - CD47
IL195400A0 (en) Aldh-2 inhibitors in the treatment of addiction
IL228597A0 (en) Isoindoline compounds for use in the treatment of cancer
EP2109687A4 (en) MICRO-RNA-BASED METHODS AND COMPOSITIONS FOR TREATING ACUTE MYELOUS LEUKEMIA (AML)
IL201211A (en) K3 ip-alpha quinoxaline inhibitors for use in combination with chemotherapeutic agents for use in the treatment of cancer
HK1148906A1 (en) Compositions and methods for cancer treatment
EP2200977A4 (en) F1F0-ATPASE INHIBITOR AND ASSOCIATED METHODS
EP2211854A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER USING BENZOPYRONE-TYPE PARP INHIBITORS
IL201367A0 (en) 2 - morpholin - 4 - yl - pyrimidines as pi3k inhibitors
PL2101731T3 (pl) Endoksyfen do zastosowania w leczeniu nowotworu
HRP20130642T1 (en) Methods and compositions for treating cancers
IL207127A0 (en) Aldh-2 inhibitors in the treatment of addiction
ZA201103964B (en) 7-hydroxy-benzoimidazole-4-yl-methanone derivatives and pbk inhibitors containing the same
IL199881A0 (en) Compositions and methods for treating hematopietic malignancies
EP2231365A4 (en) GRINDING BODY AND MANUFACTURING METHOD THEREFOR
HRP20180712T1 (hr) Postupci liječenja hematoloških oblika raka inhibitorima pnp, poput forodesina, u kombinaciji sa sredstvima protiv cd20
HK1151971A1 (en) Compounds for use in the treatment of cancer
IL209973A0 (en) Materials and methods for suppressing and/or treating neurofibroma and related tumors
EP2139908A4 (en) REMOVAL OF PROTEIN Li INVOLVED IN Li-RNAi CONSTRUCTIONS IN ANTICANCER IMMUNOTHERAPY
EP2195650A4 (en) METHOD FOR THE TREATMENT OF TUMORS AT IMMUNRIVILEGED PLACES
EP2200627A4 (en) METHOD AND COMPOSITIONS FOR TREATING MELANOMA
AU2015201757A1 (en) Compositions and methods for treating hematologic cancers targeting the SIRPalpha - CD47 interaction
HK1172547A1 (en) Activin-actrii antagonists for use in treating anemia -actrii